Warning letter
Kabana Skin Care LLC: warning letter of Jul 18, 2025
FDA warning letter 710232 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 710232 |
|---|---|
| Company | Kabana Skin Care LLC |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Jul 18, 2025 |
| Posted date | Jul 29, 2025 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 211.67(a), 211.22, 211.22(a), 211.84(d)(1), 211.100(a), 211.137, 211.165(a) |
| Inspection city | Louisville |
| Inspection ZIP | 80027 |
| Inspection start date | Feb 19, 2025 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: